Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP

Ann Hematol. 2022 Jun;101(6):1369-1371. doi: 10.1007/s00277-021-04740-4. Epub 2021 Dec 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Child
  • Humans
  • Male
  • Off-Label Use
  • Purpura, Thrombotic Thrombocytopenic* / drug therapy
  • Single-Domain Antibodies* / therapeutic use

Substances

  • Single-Domain Antibodies
  • caplacizumab